After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc, a global leader in ...

T here is still no cure for Parkinson’s disease, but the U.S. Food and Drug Administration (FDA) approved a new deep brain ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Medtronic强调，其BrainSense™技术通过实时监测大脑信号，能够对患者病情提供独特见解。公司致力于创造适应现实场景的解决方案，这一点在aDBS的开发中得到了充分体现，预计将为帕金森病治疗树立新标准。

The brain-computer interface technology personalizes therapy based on an individual’s brain activity.

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

Bullish option flow detected in Medtronic (MDT) with 13,596 calls trading, 3x expected, and implied vol increasing over 1 point to 19.29%.